Comparative Pharmacology
Head-to-head clinical analysis: TEMODAR versus TEPADINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TEMODAR versus TEPADINA.
TEMODAR vs TEPADINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Temozolomide is a prodrug that undergoes rapid nonenzymatic conversion at physiological pH to the active alkylating agent MTIC (monomethyl triazenoimidazole carboxamide). MTIC methylates DNA at the O6 position of guanine, leading to DNA mismatch repair-dependent cytotoxicity and apoptosis.
Alkylating agent that cross-links DNA, leading to inhibition of DNA replication and transcription, and cell death. Active against both dividing and non-dividing cells.
150-200 mg/m² orally once daily for 5 consecutive days of a 28-day cycle for anaplastic astrocytoma; 75 mg/m² orally daily for 42 days with radiotherapy for glioblastoma.
IV: 1 mg/kg twice daily for 4 consecutive days (total dose 8 mg/kg) or 3.5 mg/m² once daily for 5 days (total dose 17.5 mg/m²) as part of conditioning regimen prior to hematopoietic progenitor cell transplantation.
None Documented
None Documented
Terminal elimination half-life is approximately 1.8 hours. Clinically, the short half-life supports once-daily dosing; no accumulation occurs with repeated doses. The active metabolite MTIC has a half-life of about 2 hours.
Terminal elimination half-life: approximately 1.5-2.5 hours following IV administration; clinically, this short half-life supports myeloablative conditioning regimens with minimal accumulation.
Renal: ~38% of total dose recovered in urine over 7 days, primarily as unchanged temozolomide (5.6%) and metabolites (including AIC, a major metabolite). Fecal excretion is minimal (<1%). Biliary excretion is negligible.
Primarily renal: ~60-70% of the dose excreted unchanged in urine within 48 hours; biliary/fecal elimination accounts for <5%.
Category C
Category C
Antineoplastic (alkylating agent)
Antineoplastic (alkylating agent)